The gum disease vaccine developer has spun out of University of Melbourne with series A funding from investors including CSL.

Denteric, a UK-based periodontal gum disease vaccine developer spun out of University of Melbourne, attracted $14m of series A funding today from investors including biotechnology producer CSL. The round included University of Melbourne itself as well as the Australian government-backed Biomedical Translation Fund, which is managed by venture capital firm Brandon Capital. Denteric is developing…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.